Delivery Order SPE2DB22D2214-SPE2DB24FS5LM
Award Date
6/20/24
Potential Completion Date
6/21/24
Potential Value
$25K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $1,182.96, was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, particularly the Department of Defense (DoD) and Veterans Affairs (VA) healthcare systems. The contract is a Delivery Order under a larger...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency. The $1,684.96 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on June 17, 2025, with a completion date of June 18, 2025. The contract is not set aside and does not mention any subcontractors. AmerisourceBergen Drug Corp holds a substantial $999,999,999.00...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The contract, valued at $1,577.28, was awarded to AmerisourceBergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of April 17, 2024. AmerisourceBergen Drug Corp...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has a ceiling value of $37,158.20 and a completion date of May 29, 2024. It is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA), a defense agency. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999.00...
The federal contract award provides for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA) Troop Support Medical. The award was made to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. This is a firm fixed price delivery order with a ceiling value of $1,971.60 and a performance period through March 19, 2024. Amerisourcebergen Drug Corp...
This federal contract award is for the delivery of the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical product. The contract, with a ceiling value of $19,716.00, was awarded by the Defense Logistics Agency (DLA) to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA, valued up to $999,999,999.00 through December 31, 2025. This...
This federal contract award is for the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,361.62 fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of November 13, 2024. The contract is not designated with any set-aside requirements, indicating open competition. AmerisourceBergen holds a $999,999,999...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $13,471.20, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. This is a delivery order contract with a firm fixed price pricing type and a completion date of September 13, 2021. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The award, valued at $118,296.00, is a firm fixed-price delivery order placed by the Defense Logistics Agency (DLA), a defense agency within the Department of Defense. The award is not associated with a set-aside program and has a period of performance through June 12, 2024. Amerisourcebergen is a major supplier of...
This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccines to the Defense Logistics Agency (DLA). The contract, valued at $69,524.40, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of September 11, 2024. The contract is not designated with a set-aside requirement, indicating open competition....